Amendments to the Claims:

1-34 (Cancelled)

35. (Currently amended) A method for treating a human patient for congestive heart failure, comprising administering a single unit dose of a therapeutically effective amount of a recombinant FGF-2 or an angiogenically active fragment or an angiogenically active mutein thereof into one or more coronary vessels or into a peripheral vein in a human patient in need of treatment for said congestive heart failure, said therapeutically effective amount being about 0.2 μg/kg to 48 μg/kg of patient weight, wherein said angiogenically active mutein has at least 75% sequence identity to the FGF-2 of SEQ ID NO:2 and retains at least 50% of the angiogenic activity of the FGF-2 of SEQ ID NO:2, and wherein said angiogenically active fragment has about 80% of the 146 residues of the FGF-2 of SEQ ID NO: 2 and retains at least 50% of the angiogenic activity of the FGF-2 of SEQ ID NO: 2; wherein administration of said single unit dose provides for coronary angiogenesis in said patient.

36. (Currently amended) The method of claim 35, wherein said ~~therapeutically effective amount of said recombinant FGF-2 or said angiogenically active fragment or said angiogenically active mutein thereof~~unit dose is administered by infusion.

37. (Previously presented) The method of claim 35, wherein said recombinant FGF-2 has the amino acid sequence of SEQ ID NO: 2.

38. (Currently amended) The method of claim 37, further comprising the step of administering to said human patient about 10 U/kg to 80 U/kg of heparin within 30 minutes of administering said ~~recombinant FGF-2 of SEQ ID NO: 2 or said angiogenically active fragment or said angiogenically active mutein thereof~~unit dose.

39. (Currently amended) The method of claim 38, wherein said ~~therapeutically effective amount of said recombinant FGF-2 of SEQ ID NO: 2 or said angiogenically active fragment or~~

Received from < > at 9/8/03 5:43:00 PM [Eastern Daylight Time]

~~said angiogenically active mutein thereof~~unit dose is administered into one or more coronary vessels.

40. (Previously presented) The method of claim 39, wherein said therapeutically effective amount of said recombinant FGF-2 of SEQ ID NO: 2 or said angiogenically active fragment or said angiogenically active mutein thereof is about 24 μg/kg to 48 μg/kg.

41. (Currently amended) The method of claim 38, wherein said ~~therapeutically effective amount of said recombinant FGF-2 of SEQ ID NO: 2 or said angiogenically active fragment or said angiogenically active mutein thereof~~ unit dose is administered into a peripheral vein.

42. (Previously presented) The method of claim 41, wherein said therapeutically effective amount of said recombinant FGF-2 of SEQ ID NO: 2 or said angiogenically active fragment or said angiogenically active mutein thereof is about 18 μg/kg to 36 μg/kg.

43. (Currently amended) A method for treating a human patient for congestive heart failure, comprising administering a single unit dose of a recombinant FGF-2 or an angiogenically active fragment or an angiogenically active mutein thereof into one or more coronary vessels or into a peripheral vein in a human patient in need of treatment for congestive heart failure, said unit dose comprising from about .008 mg to 7.2 mg of said recombinant FGF-2 or said angiogenically active fragment or said angiogenically active mutein thereof, wherein said angiogenically active mutein has at least 75% sequence identity to the FGF-2 of SEQ ID NO:2 and retains at least 50% of the angiogenic activity of the FGF-2 of SEQ ID NO:2, and wherein said angiogenically active fragment has about 80% of the 146 residues of the FGF-2 of SEQ ID NO: 2 and retains at least 50% of the angiogenic activity of the FGF-2 of SEQ ID NO: 2; wherein administration of said unit dose provides for coronary angiogenesis in said patient.

44. (Previously presented) The method of claim 43, wherein said unit dose is administered by infusion.

Received from < > at 9/8/03 5:43:00 PM [Eastern Daylight Time]

45. (Previously presented) The method of claim 43, wherein said FGF-2 has the amino acid sequence of SEQ ID NO: 2.

46. (Previously presented) The method of claim 45, wherein said unit dose comprises 0.3 mg to 3.5 mg of said recombinant FGF-2 of SEQ ID NO: 2 or said angiogenically active fragment or said angiogenically active mutein thereof.

47. (Previously presented) The method of claim 45, further comprising the step of administering 10 U/kg to 80 U/kg of heparin to said patient within about 30 minutes of administering said unit dose, wherein said heparin is administered by intravenous or intracoronary administration.

48. (Currently amended) The method of claim 47, wherein said unit dose is administered into one or more coronary ~~arteries~~vessels.

49. (Previously presented) The method of claim 47, wherein said unit dose is administered into a peripheral vein.

50. (Previously presented) The method of claim 45, wherein said single unit dose produces a therapeutic benefit against congestive heart failure in said human patient that lasts at least 4 months.

51. (Previously presented) The method of claim 50, wherein said therapeutic benefit in said human patient lasts 6 months.

52. (Previously presented) The method of claim 51, wherein said single unit dose produces a therapeutic benefit of such magnitude and duration in said human patient such that administration of a second unit dose is not required for about 6 months.

Received from < > at 9/8/03 5:43:00 PM [Eastern Daylight Time]